ArticleInflammopharmacology2003
The reduction of food intake induced in mice by benzylamine and its derivatives.
Article in Inflammopharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- 4-methyl benzylamine stimulates food consumption and counteracts the hypophagic effects of amphetamine acting on brain Shaker-like Kv1.1 channels.British journal of pharmacology · 2006Article
- Effects of oral administration of benzylamine on glucose tolerance and lipid metabolism in rats.Journal of physiology and biochemistry · 2005Article
- Amine oxidase substrates for impaired glucose tolerance correction.Journal of physiology and biochemistry · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterisation of the pharmacological profile of non-physiological amine oxidase substrates could help to identify the endogenous role of this class of enzymes. Previous studies have suggested that benzylamine, a common non-physiological substrate for monoamine and tissue-bound or soluble benzylamine oxidases, could behave as a potassium channel blocking agent. Potassium channel blockers are known to modify several forms of animal behaviour including food consumption. To characterise further the pharmacological profile of benzylamine and the role of amine oxidases, we have studied the effect of benzylamine on mice food intake. Our results confirm that benzylamine produces a reduction in mice feeding in a similar manner to that obtained by amphetamine. The anorectic effect of benzylamine and amphetamine in mice was potentiated by pretreatment with amine oxidase inhibitors. In addition, the introduction of substituents in the aromatic ring of benzylamine did not produce compounds with a higher anorectic potency than the one measured with benzylamine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.